U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening
U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening
$3,750.00
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.
Publisher: Medtech Insight
- Description
- Contents
- Samples
Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. In the fight against cancer, diagnostic ultrasound imaging, minimally invasive biopsy, and tissue screening are among the methods that allow physicians to detect malignancies at their earliest and most treatable stages.
In 2012, approximately 92.0 million oncology-related diagnostic ultrasound, minimally invasive biopsy, and tissue screening procedures were performed in the U.S. Together, these procedures generated approximately $1.1 billion in corresponding product sales; it is expected that during the forecast period covered by this report, sales of diagnostic ultrasound, minimally invasive biopsy, and tissue screening products for oncology-related indications will increase at a compound annual rate of 3.9%, reaching nearly $1.4 billion in the year 2017.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.
Covered topics in this report include an overview of cancer in the U.S. including discussions of the different forms of the disease; automated and semi-automated tissue screening technologies; capacitive micromachined ultrasonic transducers; contrast-enhanced ultrasound; core needle biopsy systems; diagnostic ultrasound systems; Doppler and tissue harmonic imaging; fine-needle aspiration; human papilloma virus testing systems; minimally invasive biopsy; Papanicolaou smear testing systems; photoacoustic imaging; risk factors for cancer development; statistics covering new cancer cases, cancer prevalence, and cancer-related deaths; tissue elastography; and vacuum-assisted biopsy systems; among others
Table of Contents
1. CANCER STATISTICS UPDATE ………………………………………………………. 1-1
1.1 Acquired Capabilities of Cancer Cells ……………………………………….. 1-2
1.2 Cataloging Genomic Alterations Involved in the
Development of Cancer…………………………………………………………… 1-4
1.3 Risk Factors Associated with the Development of Cancer ……………. 1-5
1.4 Cancer Staging………………………………………………………………………. 1-6
1.5 New Cancer Cases, Cancer Prevalence,
and Deaths Due to Cancer………………………………………………………. 1-6
1.6 Clinical and Statistical Data for Selected
Types of Cancer …………………………………………………………………….. 1-8
1.6.1 Brain and Other Nervous System Cancers…………………… 1-8
1.6.1.1 Etiology ………………………………………………….. 1-11
1.6.1.2 Epidemiology…………………………………………… 1-13
1.6.2 Breast Cancer ……………………………………………………….. 1-13
1.6.2.1 Etiology ………………………………………………….. 1-15
1.6.2.2 Epidemiology…………………………………………… 1-16
1.6.3 Colorectal Cancer…………………………………………………… 1-16
1.6.3.1 Etiology ………………………………………………….. 1-18
1.6.3.2 Epidemiology…………………………………………… 1-19
1.6.4 Kidney/Renal Pelvis Cancer…………………………………….. 1-21
1.6.4.1 Etiology ………………………………………………….. 1-22
1.6.4.2 Epidemiology…………………………………………… 1-23
1.6.5 Leukemia………………………………………………………………. 1-23
1.6.5.1 Etiology ………………………………………………….. 1-25
1.6.5.2 Epidemiology…………………………………………… 1-26
1.6.6 Lung/Bronchus Cancer……………………………………………. 1-27
1.6.6.1 Etiology ………………………………………………….. 1-30
1.6.6.2 Epidemiology…………………………………………… 1-31
1.6.7 Lymphoma…………………………………………………………….. 1-31
1.6.7.1 Etiology ………………………………………………….. 1-35
1.6.7.2 Epidemiology…………………………………………… 1-36
1.6.8 Melanoma……………………………………………………………… 1-36
1.6.8.1 Etiology ………………………………………………….. 1-40
1.6.8.2 Epidemiology…………………………………………… 1-41
1.6.9 Oral Cavity and Pharyngeal Cancers ………………………… 1-42
1.6.9.1 Etiology ………………………………………………….. 1-44
1.6.9.2 Epidemiology…………………………………………… 1-44
1.6.10 Ovarian Cancer ……………………………………………………… 1-46
1.6.10.1 Etiology ………………………………………………….. 1-48
1.6.10.2 Epidemiology…………………………………………… 1-50
1.6.11 Pancreatic Cancer………………………………………………….. 1-50
1.6.11.1 Etiology ………………………………………………….. 1-52
1.6.11.2 Epidemiology…………………………………………… 1-53
1.6.12 Prostate Cancer …………………………………………………….. 1-53
1.6.12.1 Etiology ………………………………………………….. 1-55
1.6.12.2 Epidemiology…………………………………………… 1-57
1.6.13 Thyroid Cancer………………………………………………………. 1-59
1.6.13.1 Etiology ………………………………………………….. 1-60
1.6.13.2 Epidemiology…………………………………………… 1-61
1.6.14 Urinary Bladder Cancer…………………………………………… 1-63
1.6.14.1 Etiology ………………………………………………….. 1-64
1.6.14.2 Epidemiology…………………………………………… 1-65
1.6.15 Uterine Cancer ………………………………………………………. 1-65
1.6.15.1 Etiology ………………………………………………….. 1-67
1.6.15.2 Epidemiology…………………………………………… 1-68
Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths
for Selected Types of Cancer…………………………………………………… 1-9
Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures……. 1-14
Exhibit 1-3: Breast Cancer, Facts And Figures…………………………………………… 1-17
Exhibit 1-4: Colorectal Cancer, Facts And Figures……………………………………… 1-20
Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures ……………………… 1-24
Exhibit 1-6: Leukemia, Facts and Figures …………………………………………………. 1-28
Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures………………………………. 1-32
Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures …………………………………… 1-37
Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures ……………………………. 1-38
Exhibit 1-10: Melanoma of the Skin, Facts and Figures ………………………………… 1-43
Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures……………. 1-47
Exhibit 1-12: Ovarian Cancer, Facts and Figures…………………………………………. 1-51
Exhibit 1-13: Pancreatic Cancer, Fact and Figures ………………………………………. 1-54
Exhibit 1-14: Prostate Cancer, Facts And Figures………………………………………… 1-58
Exhibit 1-15: Thyroid Cancer, Fact and Figures …………………………………………… 1-62
Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures ……………………………….. 1-66
Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures ……………………… 1-70
Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures……………………….. 1-71
2. U.S. MARKETS FOR ONCOLOGY-RELATED DIAGNOSTIC
ULTRASOUND, MINIMALLY INVASIVE BIOPSY, AND TISSUE
SCREENING PRODUCTS………………………………………………………………… 2-1
2.1 Diagnostic Ultrasound Systems, Market Analysis ……………………….. 2-2
2.1.1 Technologies …………………………………………………………… 2-5
2.1.1.1 Doppler Imaging………………………………………… 2-8
2.1.1.2 Tissue Harmonic Imaging……………………………. 2-9
2.1.1.3 Tissue Elastography…………………………………. 2-10
2.1.1.4 Contrast-Enhanced Ultrasound ………………….. 2-12
2.1.2 Procedure Volumes………………………………………………… 2-14
2.1.3 Products ……………………………………………………………….. 2-16
2.1.4 Market Forecast …………………………………………………….. 2-65
2.1.5 Competitive Analysis ………………………………………………. 2-69
2.2 Minimally Invasive Biopsy Systems, Market Analysis…………………. 2-83
2.2.1 Technologies …………………………………………………………. 2-83
2.2.1.1 Core Needle/Fine Needle/Multipurpose
Tool-Assisted Biopsy………………………………… 2-84
2.2.1.2 Vacuum-Assisted Biopsy…………………………… 2-85
2.2.2 Procedure Volumes………………………………………………… 2-86
2.2.3 Products ……………………………………………………………….. 2-87
2.2.4 Market Forecast …………………………………………………….. 2-89
2.2.5 Competitive Analysis ………………………………………………. 2-99
2.3 Tissue Screening, Market Analysis………………………………………… 2-103
2.3.1 Technologies ……………………………………………………….. 2-105
2.3.2 Procedure Volumes………………………………………………. 2-106
2.3.3 Products ……………………………………………………………… 2-108
2.3.4 Market Forecast …………………………………………………… 2-113
2.3.5 Competitive Analysis …………………………………………….. 2-119
Exhibit 2-1: Oncology-Related Diagnostic Ultrasound,
Minimally Invasive Biopsy, and Tissue Screening,
Combined Procedure Volumes Forecast, 2012-2017…………………… 2-3
Exhibit 2-2: Oncology-Related Diagnostic Ultrasound,
Minimally Invasive Biopsy, and Tissue Screening Products,
Combined Market Forecast, 2012-2017 ……………………………………. 2-4
Exhibit 2-3: Oncology-Related Diagnostic Ultrasound,
Procedure Volumes Forecast, 2012-2017 ………………………………… 2-17
Exhibit 2-4: 2014, Selected Diagnostic Ultrasound Systems………………………… 2-20
Exhibit 2-5: Oncology-Related Diagnostic Ultrasound Systems,
Market Forecast, 2012-2017 ………………………………………………….. 2-70
Exhibit 2-6: 2012, Oncology-Related Diagnostic Ultrasound Systems
Market, Share by Supplier……………………………………………………… 2-82
Exhibit 2-7: Minimally Invasive Biopsy,
Procedure Volumes Forecast, 2012-2017 ………………………………… 2-88
Exhibit 2-8: 2014, Selected Minimally Invasive Biopsy Products…………………… 2-90
Exhibit 2-9: Minimally Invasive Biopsy Products,
Market Forecast, 2012-2017 ………………………………………………… 2-100
Exhibit 2-10: 2012, Minimally Invasive Biopsy Products Market,
Share by Supplier……………………………………………………………….. 2-104
Exhibit 2-11: Tissue Screening, Procedure Volumes Forecast, 2012-2017 ……. 2-109
Exhibit 2-12: 2014, Selected Tissue Screening Products…………………………….. 2-114
Exhibit 2-13: Tissue Screening Products, Market Forecast, 2012-2017…………. 2-120
Exhibit 2-14: 2012, Tissue Screening Products Market, Share by Supplier ……. 2-124
3. COMPANY PROFILES…………………………………………………………………….. 3-1
3.1 Analogic Corporation………………………………………………………………. 3-1
3.2 Bard Biopsy Systems/ Bard Peripheral Vascular, Inc./
C.R. Bard, Inc………………………………………………………………………… 3-3
3.3 Becton, Dickinson and Company ……………………………………………… 3-5
3.4 CareFusion Corporation ………………………………………………………….. 3-7
3.5 Fujifilm SonoSite, Inc./Fujifilm Medical Systems USA, Inc./
Fujifilm Holdings America Corporation/Fujifilm ……………………………. 3-7
3.6 GE Healthcare, Inc./General Electric Company ………………………….. 3-9
3.7 Hitachi Aloka Medical America/Hitachi Aloka Medical/
Hitachi Medical/Hitachi ………………………………………………………….. 3-12
3.8 Hologic, Inc………………………………………………………………………….. 3-14
3.9 Mammotome/Devicor Medical Products, Inc. ……………………………. 3-16
3.10 Mindray Medical USA Corporation/
Mindray Medical International LTD………………………………………….. 3-17
3.11 Philips Healthcare, Inc./Royal Philips NV …………………………………. 3-19
3.12 Qiagen NV…………………………………………………………………………… 3-21
3.13 Samsung Medison/Samsung Electronics America, Inc./
Samsung Electronics Co., LTD/Samsung ………………………………… 3-22
3.14 Siemens Healthcare/Siemens Medical Solutions USA, Inc./
Siemens AG ………………………………………………………………………… 3-25
3.15 Toshiba America Medical Systems, Inc./
Toshiba Corporation……………………………………………………………… 3-27
APPENDIX: COMPANY LISTING……………………………………………………………… A-1
Figure: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
United Kingdom, Surgical Procedure Volumes 
Sign up to the